MX2024009969A - Formulacion liquida de toxina botulinica y uso de la misma. - Google Patents
Formulacion liquida de toxina botulinica y uso de la misma.Info
- Publication number
- MX2024009969A MX2024009969A MX2024009969A MX2024009969A MX2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- liquid formulation
- relates
- present
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156850 | 2022-02-15 | ||
| PCT/EP2023/053634 WO2023156385A1 (en) | 2022-02-15 | 2023-02-14 | Liquid botulinum toxin formulation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009969A true MX2024009969A (es) | 2024-09-18 |
Family
ID=80682748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009969A MX2024009969A (es) | 2022-02-15 | 2023-02-14 | Formulacion liquida de toxina botulinica y uso de la misma. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250161186A1 (https=) |
| EP (1) | EP4479012A1 (https=) |
| JP (1) | JP2025504247A (https=) |
| KR (1) | KR20240150786A (https=) |
| CN (1) | CN118829442A (https=) |
| AR (1) | AR128515A1 (https=) |
| AU (1) | AU2023222384A1 (https=) |
| CA (1) | CA3243198A1 (https=) |
| CO (1) | CO2024010938A2 (https=) |
| IL (1) | IL314995A (https=) |
| MX (1) | MX2024009969A (https=) |
| TW (1) | TW202400223A (https=) |
| WO (1) | WO2023156385A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228877A1 (en) | 2024-04-29 | 2025-11-06 | Merz Therapeutics GmbH | Botulinum toxin for the preventive treatment of migraine |
| WO2026021713A1 (en) | 2024-07-23 | 2026-01-29 | Merz Therapeutics GmbH | Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06192118A (ja) * | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
| US7037680B2 (en) * | 1993-09-21 | 2006-05-02 | The United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| AU4746096A (en) * | 1995-06-06 | 1996-12-24 | Wisconsin Alumni Research Foundation | Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin |
| PT2271670E (pt) | 2008-03-14 | 2014-11-28 | Allergan Inc | Ensaio imunobaseado da atividade do serotipo a da toxina botulínica |
| ES2653249T3 (es) | 2011-09-29 | 2018-02-06 | Cellsnap, Llc | Composiciones y métodos para ensayos de toxigenicidad |
| AU2014301116B2 (en) | 2013-06-28 | 2019-11-14 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells |
| WO2017188618A1 (en) * | 2016-04-26 | 2017-11-02 | Korea Prime Pharm Co., Ltd. | A novel composition comprising botulinum toxin |
| CA3060669A1 (en) * | 2017-04-28 | 2018-11-01 | Bonti, Inc. | Botulinum neurotoxins production methods |
| MX2021014486A (es) * | 2020-03-31 | 2022-01-04 | Obi Pharma Inc | Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo. |
-
2023
- 2023-02-14 EP EP23704173.6A patent/EP4479012A1/en active Pending
- 2023-02-14 WO PCT/EP2023/053634 patent/WO2023156385A1/en not_active Ceased
- 2023-02-14 US US18/838,546 patent/US20250161186A1/en active Pending
- 2023-02-14 CA CA3243198A patent/CA3243198A1/en active Pending
- 2023-02-14 AR ARP230100337A patent/AR128515A1/es unknown
- 2023-02-14 IL IL314995A patent/IL314995A/en unknown
- 2023-02-14 JP JP2024547665A patent/JP2025504247A/ja active Pending
- 2023-02-14 AU AU2023222384A patent/AU2023222384A1/en active Pending
- 2023-02-14 MX MX2024009969A patent/MX2024009969A/es unknown
- 2023-02-14 KR KR1020247030631A patent/KR20240150786A/ko active Pending
- 2023-02-14 TW TW112105173A patent/TW202400223A/zh unknown
- 2023-02-14 CN CN202380022129.XA patent/CN118829442A/zh active Pending
-
2024
- 2024-08-12 CO CONC2024/0010938A patent/CO2024010938A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314995A (en) | 2024-10-01 |
| US20250161186A1 (en) | 2025-05-22 |
| JP2025504247A (ja) | 2025-02-06 |
| WO2023156385A1 (en) | 2023-08-24 |
| CA3243198A1 (en) | 2023-08-24 |
| KR20240150786A (ko) | 2024-10-16 |
| TW202400223A (zh) | 2024-01-01 |
| EP4479012A1 (en) | 2024-12-25 |
| CO2024010938A2 (es) | 2024-09-19 |
| AR128515A1 (es) | 2024-05-15 |
| CN118829442A (zh) | 2024-10-22 |
| AU2023222384A1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024010938A2 (es) | Formulación líquida de toxina botulínica y uso de la misma | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| BR112021017890A2 (pt) | Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| CR20190400A (es) | Formulaciones de anticuerpo monoclonal anti-vrs | |
| BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
| ECSP088962A (es) | Nuevos herbicidas | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| AR052247A1 (es) | Un metodo y una composicion cosmetica par inhibir o controlar simultaneamente la transpiracion y/o mal olor axilar y mejorar o controlar el oscurecimiento de la piel | |
| BR112022001678A2 (pt) | Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes | |
| MXPA02007059A (es) | Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado. | |
| BRPI0810118A8 (pt) | Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento | |
| MX2019003611A (es) | Formulaciones novedosas. | |
| BR112022013204A2 (pt) | Usos de uma composição e de uma preparação combinada | |
| AR097599A1 (es) | Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel | |
| CO2020016014A2 (es) | Formulación de proteína de fusión ctla4-ig | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| BR112022026699A2 (pt) | Mecanismo de liberação de fragrâncias, método e usos do mesmo | |
| CO2024010940A2 (es) | Formulación líquida de toxina botulínica y uso de la misma | |
| AR109277A1 (es) | Composición y método para el tratamiento de las afecciones de la piel | |
| MXPA02002117A (es) | Uso de productos leguminosos para el tratamiento de agresiones externas. | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| AR004326A1 (es) | Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista. | |
| MX2019008115A (es) | Formulaciones topicas de detomidina. | |
| BR112022021006A2 (pt) | Métodos para reduzir ou prevenir a colonização de clostridioides difficile |